16
Tables
Table 6. Non-oral Glucocorticoid Formulations and Risk of
Glucocorticoid-induced Adrenal Insufficiency
Prevalence of glucocorticoid-induced adrenal insufficiency
1
Inhaled
glucocorticoids
• Overall: 7.8% (confidence interval [CI] 4.2–13.9)
• Short-term use (<1 month): 1.4% (CI 0.3–7.4)
• Medium-term use (1–12 months): 11.9% (CI 5.8–23.1)
• Long-term use (>12 months): 27.4% (CI 17.7–39.8)
• Low dose use: 2.4% (0.6–9.3)
• Intermediate dose use: 8.5% (4.2–16.8)
• High dose
b
use: 21.5% (12.0–35.5)
Intra-articular
glucocorticoids
52.2% (40.5–63.6)
